Regenxbio Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Rockville MD United States (2009)

Organization Overview

First Clinical Trial
2017
NCT03066258
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Regenxbio Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

aflibercept (zaltrap) (1 trial)

ranibizumab (lucentis) (2 trials)

rgx-314 (6 trials)

Drugs in Phase 2 Trials (3)

rgx-121 (2 trials)

rgx-202 (1 trial)

rgx-381 (1 trial)

Drugs in Phase 1 Trials (1)

rgx-111 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 2)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis I (Phase 1)

Mucopolysaccharidosis II (Phase 2)

Retinal Diseases (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 7